Article

Functional damage is key to monitoring glaucoma

New York-The ideal monitor of glaucoma progression should have high sensitivity, high specificity, be resistant to fluctuations of the condition, require few confirmatory tests, have broad sensitivity at all stages of the disease, and be easy to interpret, according to David S. Greenfield, MD, who spoke at the Glaucoma 2004 meeting here.

New York-The ideal monitor of glaucoma progression should have high sensitivity, high specificity, be resistant to fluctuations of the condition, require few confirmatory tests, have broad sensitivity at all stages of the disease, and be easy to interpret, according to David S. Greenfield, MD, who spoke at the Glaucoma 2004 meeting here.

At this time such a monitor is not yet available, but progress is being made, said Dr. Greenfield, associate professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami.

Seven trials conducted over the last 2 decades have described a number of risk factors for progression, he said, but with a bothersome lack of agreement among the findings.

Thus, it becomes essential to establish these confidence limits quantitatively to differentiate stable eyes from those in which glaucoma is progressing.

The Humphrey Glaucoma Progression Analysis software (Carl Zeiss Meditec) uses data collected from 16 clinical sites over 6 years from the Early Manifest Glaucoma Trial and represents "a new advancement in our ability to take some broad steps," Dr. Greenfield said.

"It allows one to evaluate a sequence of SITA [Swedish Interactive Threshold Algorithm] visual fields critically in a way that statistically assesses progression," Dr. Greenfield said.

In the creation of this software, significance limits were obtained by testing a patient four times within a period of 1 month. Glaucoma would not be expected to pro-gress in this period and repeated testing provides a means of creating variability estimates. Patient threshold values are compared with these estimates after creating a baseline image formed from two reliable visual fields.

Subsequent follow-up examination results are compared with the baseline examination in order to identify specific points that are suspected to have had progression. A significant change in three points on two consecutive visual fields indicates "possible progression"; a significant change in three points on three consecutive visual fields suggests "probable progression." Thus, five visual field tests are needed to determine progression.

Standard automated perimetry is an established technique that has many advantages, said Jody R. Piltz-Seymour, MD, director of glaucoma service and glaucoma fellowship at the Scheie Eye Institute, and associate professor of ophthalmology, University of Pennsylvania, Philadelphia.

The SITA test, using newer Humphrey perimeters, allows threshold testing in half the time of full threshold testing, Dr. Piltz-Seymour said.

The program uses information about many factors-age, different patterns of glaucomatous loss, and so on-to predict future responses continuously as the test proceeds.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
© 2025 MJH Life Sciences

All rights reserved.